HIV-1 subtype C-infected individuals maintaining high viral load as potential targets for the "test-and-treat" approach to reduce HIV transmission.

PubWeight™: 1.36‹?› | Rank: Top 10%

🔗 View Article (PMC 2853582)

Published in PLoS One on April 12, 2010

Authors

Vladimir Novitsky1, Rui Wang, Hermann Bussmann, Shahin Lockman, Marianna Baum, Roger Shapiro, Ibou Thior, Carolyn Wester, C William Wester, Anthony Ogwu, Aida Asmelash, Rosemary Musonda, Adriana Campa, Sikhulile Moyo, Erik van Widenfelt, Madisa Mine, Claire Moffat, Mompati Mmalane, Joseph Makhema, Richard Marlink, Peter Gilbert, George R Seage, Victor DeGruttola, M Essex

Author Affiliations

1: Harvard School of Public Health AIDS Initiative, Department of Immunology and Infectious Diseases, Harvard School of Public Health, Boston, Massachusetts, United States of America.

Articles citing this

HIV prevention transformed: the new prevention research agenda. Lancet (2011) 4.23

Extended high viremics: a substantial fraction of individuals maintain high plasma viral RNA levels after acute HIV-1 subtype C infection. AIDS (2011) 3.95

HIV-1 treatment as prevention: the good, the bad, and the challenges. Curr Opin HIV AIDS (2011) 3.39

Antiretroviral treatment of HIV-1 prevents transmission of HIV-1: where do we go from here? Lancet (2013) 2.31

Antiviral agents and HIV prevention: controversies, conflicts, and consensus. AIDS (2012) 1.73

HPTN 071 (PopART): a cluster-randomized trial of the population impact of an HIV combination prevention intervention including universal testing and treatment: mathematical model. PLoS One (2014) 1.66

HIV treatment as prevention: the utility and limitations of ecological observation. PLoS Med (2012) 1.55

Phylogenetic inferences on HIV-1 transmission: implications for the design of prevention and treatment interventions. AIDS (2013) 1.10

HIV treatment as prevention: optimising the impact of expanded HIV treatment programmes. PLoS Med (2012) 1.08

Concurrency revisited: increasing and compelling epidemiological evidence. J Int AIDS Soc (2011) 1.06

Intra-host evolutionary rates in HIV-1C env and gag during primary infection. Infect Genet Evol (2013) 1.01

Evaluation of the false recent classification rates of multiassay algorithms in estimating HIV type 1 subtype C incidence. AIDS Res Hum Retroviruses (2013) 0.92

Overview of the current state of the epidemic. Curr HIV/AIDS Rep (2013) 0.91

Clinical uncertainties, health service challenges, and ethical complexities of HIV "test-and-treat": a systematic review. Am J Public Health (2013) 0.90

The HIV Epidemic: High-Income Countries. Cold Spring Harb Perspect Med (2012) 0.90

Rapid disease progression in HIV-1 subtype C-infected South African women. Clin Infect Dis (2014) 0.87

Viral diversity and diversification of major non-structural genes vif, vpr, vpu, tat exon 1 and rev exon 1 during primary HIV-1 subtype C infection. PLoS One (2012) 0.84

Characterization of acute HIV-1 infection in high-risk Nigerian populations. J Infect Dis (2012) 0.83

THE DEVELOPMENT AND FEASIBILITY OF A BRIEF RISK REDUCTION INTERVENTION FOR NEWLY HIV-DIAGNOSED MEN WHO HAVE SEX WITH MEN. J Community Psychol (2011) 0.82

Using plasma viral load to guide antiretroviral therapy initiation to prevent HIV-1 transmission. PLoS One (2012) 0.82

Linkage of viral sequences among HIV-infected village residents in Botswana: estimation of linkage rates in the presence of missing data. PLoS Comput Biol (2014) 0.82

tat Exon 1 exhibits functional diversity during HIV-1 subtype C primary infection. J Virol (2013) 0.79

Effect of early anti-retroviral therapy on the pathogenic changes in mucosal tissues of SIV infected rhesus macaques. Virol J (2012) 0.79

Can the Heterosexual HIV Epidemic be Eliminated in South Africa Using Combination Prevention? A Modeling Analysis. Am J Epidemiol (2016) 0.78

Recent HIV-1 infection: identification of individuals with high viral load setpoint in a voluntary counselling and testing centre in rural Mozambique. PLoS One (2012) 0.77

High Rate of Non-detectable HIV-1 RNA Among Antiretroviral Drug Naive HIV Positive Individuals in Nigeria. Virology (Auckl) (2013) 0.75

Beyond Risk Compensation: Clusters of Antiretroviral Treatment (ART) Users in Sexual Networks Can Modify the Impact of ART on HIV Incidence. PLoS One (2016) 0.75

Articles cited by this

Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med (2000) 41.18

Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet (2008) 36.01

Rates of HIV-1 transmission per coital act, by stage of HIV-1 infection, in Rakai, Uganda. J Infect Dis (2005) 21.08

Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med (2009) 19.90

Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science (1996) 18.38

Early antiretroviral therapy and mortality among HIV-infected infants. N Engl J Med (2008) 17.12

Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med (1997) 16.44

Class-sparing regimens for initial treatment of HIV-1 infection. N Engl J Med (2008) 8.50

Transient high levels of viremia in patients with primary human immunodeficiency virus type 1 infection. N Engl J Med (1991) 7.83

Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion. Ann Intern Med (1995) 6.90

Effects of early, abrupt weaning on HIV-free survival of children in Zambia. N Engl J Med (2008) 6.80

Response to antiretroviral therapy after a single, peripartum dose of nevirapine. N Engl J Med (2007) 6.65

HIV-1 transmission, by stage of infection. J Infect Dis (2008) 6.57

Virologic and immunologic determinants of heterosexual transmission of human immunodeficiency virus type 1 in Africa. AIDS Res Hum Retroviruses (2001) 6.00

Breastfeeding plus infant zidovudine prophylaxis for 6 months vs formula feeding plus infant zidovudine for 1 month to reduce mother-to-child HIV transmission in Botswana: a randomized trial: the Mashi Study. JAMA (2006) 5.84

Biological and virologic characteristics of primary HIV infection. Ann Intern Med (1998) 5.45

Sex differences in HIV-1 viral load and progression to AIDS. Lancet (1998) 5.24

Natural history of human immunodeficiency virus type 1 viremia after seroconversion and proximal to AIDS in a large cohort of homosexual men. Multicenter AIDS Cohort Study. J Infect Dis (2000) 3.73

High levels of human immunodeficiency virus type 1 in blood and semen of seropositive men in sub-Saharan Africa. J Infect Dis (1998) 3.46

Viral dynamics of acute HIV-1 infection. J Exp Med (1999) 3.45

Correlates of mother-to-child human immunodeficiency virus type 1 (HIV-1) transmission: association with maternal plasma HIV-1 RNA load, genital HIV-1 DNA shedding, and breast infections. J Infect Dis (2000) 3.02

Impact of small reductions in plasma HIV RNA levels on the risk of heterosexual transmission and disease progression. AIDS (2008) 2.91

Initial plasma HIV-1 RNA levels and progression to AIDS in women and men. N Engl J Med (2001) 2.68

Male viral load and heterosexual transmission of HIV-1 subtype E in northern Thailand. J Acquir Immune Defic Syndr (2002) 2.48

A seronegative case of HIV-1 subtype C infection in Botswana. Clin Infect Dis (2007) 2.39

AIDS prognosis based on HIV-1 RNA, CD4+ T-cell count and function: markers with reciprocal predictive value over time after seroconversion. AIDS (1997) 1.97

Human immunodeficiency virus type 1 subtype C molecular phylogeny: consensus sequence for an AIDS vaccine design? J Virol (2002) 1.91

Higher-than-expected rates of lactic acidosis among highly active antiretroviral therapy-treated women in Botswana: preliminary results from a large randomized clinical trial. J Acquir Immune Defic Syndr (2007) 1.90

Antiretroviral concentrations in breast-feeding infants of women in Botswana receiving antiretroviral treatment. J Infect Dis (2005) 1.70

Maternal single-dose nevirapine versus placebo as part of an antiretroviral strategy to prevent mother-to-child HIV transmission in Botswana. AIDS (2006) 1.66

The reverse transcriptase 67N 70R 215Y genotype is the predominant TAM pathway associated with virologic failure among HIV type 1C-infected adults treated with ZDV/ddI-containing HAART in southern Africa. AIDS Res Hum Retroviruses (2007) 1.64

Infant morbidity, mortality, and breast milk immunologic profiles among breast-feeding HIV-infected and HIV-uninfected women in Botswana. J Infect Dis (2007) 1.60

Response to zidovudine/didanosine-containing combination antiretroviral therapy among HIV-1 subtype C-infected adults in Botswana: two-year outcomes from a randomized clinical trial. J Acquir Immune Defic Syndr (2009) 1.45

Patterns of viral dynamics during primary human immunodeficiency virus type 1 infection. The Sydney Primary HIV Infection Study Group. J Infect Dis (1998) 1.41

Better control of early viral replication is associated with slower rate of elicited antiviral antibodies in the detuned enzyme immunoassay during primary HIV-1C infection. J Acquir Immune Defic Syndr (2009) 1.34

Identification of primary HIV-1C infection in Botswana. AIDS Care (2008) 1.29

Viral load and CD4+ T-cell dynamics in primary HIV-1 subtype C infection. J Acquir Immune Defic Syndr (2009) 1.27

Virus load and risk of heterosexual transmission of human immunodeficiency virus and hepatitis C virus by men with hemophilia. The Multicenter Hemophilia Cohort Study. J Infect Dis (2000) 1.19

Cost-effectiveness of HIV interventions: from cohort studies and clinical trials to policy. Top HIV Med (2009) 1.15

Evolution of proviral gp120 over the first year of HIV-1 subtype C infection. Virology (2008) 1.14

Rapid clearance of virus after acute HIV-1 infection: correlates of risk of AIDS. J Infect Dis (2004) 1.12

Risk factors for early and late transmission of HIV via breast-feeding among infants born to HIV-infected women in a randomized clinical trial in Botswana. J Infect Dis (2009) 1.11

Predictors of early and late mother-to-child transmission of HIV in a breastfeeding population: HIV Network for Prevention Trials 012 experience, Kampala, Uganda. J Acquir Immune Defic Syndr (2009) 1.08

Timing constraints of in vivo gag mutations during primary HIV-1 subtype C infection. PLoS One (2009) 1.06

Viral dynamics and CD4+ T cell counts in subtype C human immunodeficiency virus type 1-infected individuals from southern Africa. AIDS Res Hum Retroviruses (2005) 1.03

Natural history and risk factors associated with early and established HIV type 1 infection among reproductive-age women in Malawi. Clin Infect Dis (2008) 0.96

Plasma viral load concentrations in women and men from different exposure categories and with known duration of HIV infection. I.CO.N.A. Study Group. J Acquir Immune Defic Syndr (2000) 0.87

Articles by these authors

Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med (2011) 69.36

Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J Virol (2005) 15.61

The PRoteomics IDEntifications (PRIDE) database and associated tools: status in 2013. Nucleic Acids Res (2012) 13.14

Statistics in medicine--reporting of subgroup analyses in clinical trials. N Engl J Med (2007) 12.55

Acyclovir and transmission of HIV-1 from persons infected with HIV-1 and HSV-2. N Engl J Med (2010) 12.08

Isolation of T-cell tropic HTLV-III-like retrovirus from macaques. Science (1985) 9.27

Envelope-constrained neutralization-sensitive HIV-1 after heterosexual transmission. Science (2004) 8.60

Major glycoprotein antigens that induce antibodies in AIDS patients are encoded by HTLV-III. Science (1985) 8.53

Expanded screening for HIV in the United States--an analysis of cost-effectiveness. N Engl J Med (2005) 8.49

Sexual behavior of HIV discordant couples after HIV counseling and testing. AIDS (2003) 8.05

Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J Infect Dis (2006) 7.98

H2S as a physiologic vasorelaxant: hypertension in mice with deletion of cystathionine gamma-lyase. Science (2008) 7.89

Barriers to antiretroviral adherence for patients living with HIV infection and AIDS in Botswana. J Acquir Immune Defic Syndr (2003) 7.23

Response to antiretroviral therapy after a single, peripartum dose of nevirapine. N Engl J Med (2007) 6.65

Timing of antiretroviral therapy for HIV-1 infection and tuberculosis. N Engl J Med (2011) 6.42

Antiretroviral regimens in pregnancy and breast-feeding in Botswana. N Engl J Med (2010) 6.38

The lifetime cost of current human immunodeficiency virus care in the United States. Med Care (2006) 5.87

Breastfeeding plus infant zidovudine prophylaxis for 6 months vs formula feeding plus infant zidovudine for 1 month to reduce mother-to-child HIV transmission in Botswana: a randomized trial: the Mashi Study. JAMA (2006) 5.84

Expanded HIV screening in the United States: effect on clinical outcomes, HIV transmission, and costs. Ann Intern Med (2006) 5.53

Production of hepatitis B virus by a differentiated human hepatoma cell line after transfection with cloned circular HBV DNA. Cell (1986) 5.35

The matrix protein of human immunodeficiency virus type 1 is required for incorporation of viral envelope protein into mature virions. J Virol (1992) 5.30

Male circumcision: an acceptable strategy for HIV prevention in Botswana. Sex Transm Infect (2003) 5.26

H2S signals through protein S-sulfhydration. Sci Signal (2009) 4.54

Rapid scaling-up of antiretroviral therapy in 10,000 adults in Côte d'Ivoire: 2-year outcomes and determinants. AIDS (2008) 4.40

Recommendations for the design and use of standard virus panels to assess neutralizing antibody responses elicited by candidate human immunodeficiency virus type 1 vaccines. J Virol (2005) 4.35

Adaptation of HIV-1 to human leukocyte antigen class I. Nature (2009) 4.24

Daily acyclovir for HIV-1 disease progression in people dually infected with HIV-1 and herpes simplex virus type 2: a randomised placebo-controlled trial. Lancet (2010) 4.23

Mutations in the N-terminal region of human immunodeficiency virus type 1 matrix protein block intracellular transport of the Gag precursor. J Virol (1993) 4.20

Initial response to highly active antiretroviral therapy in HIV-1C-infected adults in a public sector treatment program in Botswana. J Acquir Immune Defic Syndr (2005) 4.19

A trial of shortened zidovudine regimens to prevent mother-to-child transmission of human immunodeficiency virus type 1. Perinatal HIV Prevention Trial (Thailand) Investigators. N Engl J Med (2000) 4.14

Activating ESR1 mutations in hormone-resistant metastatic breast cancer. Nat Genet (2013) 3.96

Extended high viremics: a substantial fraction of individuals maintain high plasma viral RNA levels after acute HIV-1 subtype C infection. AIDS (2011) 3.95

Regional differences in prevalence of HIV-1 discordance in Africa and enrollment of HIV-1 discordant couples into an HIV-1 prevention trial. PLoS One (2008) 3.94

HIV preexposure prophylaxis in the United States: impact on lifetime infection risk, clinical outcomes, and cost-effectiveness. Clin Infect Dis (2009) 3.89

Virus envelope protein of HTLV-III represents major target antigen for antibodies in AIDS patients. Science (1985) 3.81

Analysis of genetic linkage of HIV from couples enrolled in the HIV Prevention Trials Network 052 trial. J Infect Dis (2011) 3.78

Serologic identification and characterization of a macaque T-lymphotropic retrovirus closely related to HTLV-III. Science (1985) 3.74

Five-year outcomes of initial patients treated in Botswana's National Antiretroviral Treatment Program. AIDS (2008) 3.71

Characteristics of HIV-1 discordant couples enrolled in a trial of HSV-2 suppression to reduce HIV-1 transmission: the partners study. PLoS One (2009) 3.66

Molecular epidemiology of human immunodeficiency virus type 1 transmission in a heterosexual cohort of discordant couples in Zambia. J Virol (2002) 3.58

Paraneoplastic thrombocytosis in ovarian cancer. N Engl J Med (2012) 3.54

Sexual risk, nitrite inhalant use, and lack of circumcision associated with HIV seroconversion in men who have sex with men in the United States. J Acquir Immune Defic Syndr (2005) 3.54

Extended follow-up confirms early vaccine-enhanced risk of HIV acquisition and demonstrates waning effect over time among participants in a randomized trial of recombinant adenovirus HIV vaccine (Step Study). J Infect Dis (2012) 3.42

Latent TGF-β structure and activation. Nature (2011) 3.42

Hierarchical targeting of subtype C human immunodeficiency virus type 1 proteins by CD8+ T cells: correlation with viral load. J Virol (2004) 3.28

A new HTLV-III/LAV protein encoded by a gene found in cytopathic retroviruses. Science (1986) 3.20

Antigens encoded by the 3'-terminal region of human T-cell leukemia virus: evidence for a functional gene. Science (1984) 3.20

Proposal for naming host cell-derived inserts in retrovirus genomes. J Virol (1981) 3.18

Bacterial coaggregation: an integral process in the development of multi-species biofilms. Trends Microbiol (2003) 3.17

Antiretroviral therapies in women after single-dose nevirapine exposure. N Engl J Med (2010) 3.14

Identification of targetable FGFR gene fusions in diverse cancers. Cancer Discov (2013) 3.13

Cost-effectiveness of HIV treatment as prevention in serodiscordant couples. N Engl J Med (2013) 3.10

Long-term effectiveness of highly active antiretroviral therapy on the survival of children and adolescents with HIV infection: a 10-year follow-up study. Clin Infect Dis (2008) 3.09

Flexible use of nuclear import pathways by HIV-1. Cell Host Microbe (2010) 3.08

A new HTLV-III/LAV encoded antigen detected by antibodies from AIDS patients. Science (1985) 3.05

Early diagnosis of human immunodeficiency virus in infants using polymerase chain reaction on dried blood spots in Botswana's national program for prevention of mother-to-child transmission. Pediatr Infect Dis J (2008) 3.02

Dual vs single protease inhibitor therapy following antiretroviral treatment failure: a randomized trial. JAMA (2002) 2.96

Incidence of opportunistic and other infections in HIV-infected children in the HAART era. JAMA (2006) 2.96

Hydrogen sulfide as endothelium-derived hyperpolarizing factor sulfhydrates potassium channels. Circ Res (2011) 2.94

Estimating the lost benefits of antiretroviral drug use in South Africa. J Acquir Immune Defic Syndr (2008) 2.93

Feline oncornavirus-associated cell membrane antigen: evidence for an immunologically crossreactive feline sarcoma virus-coded protein. Proc Natl Acad Sci U S A (1977) 2.93

A microchip CD4 counting method for HIV monitoring in resource-poor settings. PLoS Med (2005) 2.90

H(2)S-induced vasorelaxation and underlying cellular and molecular mechanisms. Am J Physiol Heart Circ Physiol (2002) 2.90

Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trials. J Infect Dis (2012) 2.89

Cigarette smoking and the risk of systemic lupus erythematosus: a meta-analysis. Arthritis Rheum (2004) 2.88

Neutralizing antibodies to adenovirus serotype 5 vaccine vectors are directed primarily against the adenovirus hexon protein. J Immunol (2005) 2.84

Mutations in the cytoplasmic domain of human immunodeficiency virus type 1 transmembrane protein impair the incorporation of Env proteins into mature virions. J Virol (1993) 2.80

HIV-1 Langerhans' cell tropism associated with heterosexual transmission of HIV. Science (1996) 2.79

Carbon monoxide: endogenous production, physiological functions, and pharmacological applications. Pharmacol Rev (2005) 2.73

HTLV-III in symptom-free seronegative persons. Lancet (1984) 2.71

Risk behaviour and time as covariates for efficacy of the HIV vaccine regimen ALVAC-HIV (vCP1521) and AIDSVAX B/E: a post-hoc analysis of the Thai phase 3 efficacy trial RV 144. Lancet Infect Dis (2012) 2.68

Human immunodeficiency virus vpr gene encodes a virion-associated protein. AIDS Res Hum Retroviruses (1990) 2.67

Hydrogen sulfide is an endogenous stimulator of angiogenesis. Proc Natl Acad Sci U S A (2009) 2.66

Hydrogen sulfide-induced relaxation of resistance mesenteric artery beds of rats. Am J Physiol Heart Circ Physiol (2004) 2.62

Complete transfer of perceptual learning across retinal locations enabled by double training. Curr Biol (2008) 2.62

Randomized, controlled evaluation of a prototype informed consent process for HIV vaccine efficacy trials. J Acquir Immune Defic Syndr (2003) 2.60

Open reading frame vpr of simian immunodeficiency virus encodes a virion-associated protein. J Virol (1990) 2.60

Mitochondrial outer-membrane protein FUNDC1 mediates hypoxia-induced mitophagy in mammalian cells. Nat Cell Biol (2012) 2.56